Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of paracetamol (acetaminophen), pregabalin, and dexamethasone. Paracetamol is an analgesic and antipyretic that works primarily by inhibiting prostaglandin synthesis in the central nervous system. Pregabalin is a synthetic analog of gamma-aminobutyric acid (GABA) with analgesic, anticonvulsant, and anxiolytic effects; it binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing neurotransmitter release. Dexamethasone is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties; it acts by binding to glucocorticoid receptors to modulate gene expression and suppress inflammatory mediators. This combination has been studied for perioperative pain management, particularly for reducing postoperative pain and opioid requirements after surgeries such as abdominal hysterectomy or tonsillectomy[1][2][4]. While some studies show benefits in reducing nausea, vomiting, or rescue analgesia use when dexamethasone is included[1][3], overall evidence suggests no significant reduction in morphine consumption or pain scores compared to paracetamol alone for certain procedures[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + pregabalin + dexamethasone.